Company Encyclopedia
View More
name
CSPC PHARMA
01093.HK
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. It also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries.
1.450 T
01093.HKMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking0/48
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE11.32%B
    • Profit Margin14.83%A
    • Gross Margin63.99%A
  • Growth ScoreD
    • Revenue YoY-17.74%E
    • Net Profit YoY-34.85%D
    • Total Assets YoY-2.17%D
    • Net Assets YoY-2.63%D
  • Cash ScoreD
    • Cash Flow Margin674.32%C
    • OCF YoY-17.74%E
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreB
    • Gearing Ratio24.21%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Core products under pressure, CSPC PHARMA's revenue and profit both decline in the first three quarters

    CSPC PHARMA's performance report for the first three quarters of 2025 shows that the company's total revenue was 19.891 billion yuan, a year-on-year decrease of 12.32%; the profit attributable to shareholders was 3.511 billion yuan, a year-on-year decrease of 7.1%. The decline in performance was mainly due to a 17.2% drop in the revenue from the prescription drug business, which accounted for 77%. Revenues from neurological drugs, anti-tumor drugs, anti-infective drugs, and cardiovascular drugs fell by 21.6%, 56.8%, 22.7%, and 17.8%, respectively. The company adopted a low-price strategy, with 8 out of 15 products selected at the lowest price, affected by drug centralized procurement and adjustments in the medical insurance catalog prices

    BambooWorks·
    HK
    01093
    +0.78%
    BambooWorks·
    HK
    01093
    +0.78%

    CSPC Pharma rises as product obtains clinical trial approval in US

    CSPC Pharmaceutical Group Ltd's shares rose 5.2% to HK$7.95 after their siRNA drug, SYH2061 Injection, received FDA approval for clinical trials in the US. The drug also received approval in China in October 2025. The stock has increased 65.7% YTD, while the Hang Seng Biotech Index is up 80.2%.

    Reuters·
    HK
    01093
    +0.78%
    Reuters·
    HK
    01093
    +0.78%

    CSPC PHARMA SYH2056 tablets approved to start clinical trials

    CSPC PHARMA announced that its developed chemical drug Class 1 new drug selective 5-hydroxytryptamine 2A receptor "5-HT2A receptor" agonist (SYH2056 tablets) has been approved by the National Medical Products Administration of China to conduct clinical trials in China. The approved clinical indication is for the treatment of depression

    AASTOCKS·
    HK
    01093
    +0.78%
    AASTOCKS·
    HK
    01093
    +0.78%

    Nomura lowers CSPC PHARMA's target price to 9.11 yuan, continues to recommend "buy," expects sales to recover in the coming quarters

    Nomura Securities has lowered the target price for CSPC PHARMA to HKD 9.11, maintaining a "Buy" rating. Although CSPC PHARMA's revenue and profit declined in the first three quarters, revenue showed growth in the third quarter. Management expects positive growth in drug sales by 2026, with an increase in R&D spending. Nomura has revised down its revenue and profit forecasts for 2025 and 2026 but expects sales to gradually recover in the coming quarters

    AASTOCKS·
    HK
    01093
    +0.78%
    AASTOCKS·
    HK
    01093
    +0.78%

    According to "Blue Chip," CSPC PHARMA's net profit for the first three quarters is RMB 3.51 billion, a year-on-year decrease of 7.1%

    CSPC PHARMA announced its performance for the first three quarters ending September this year, with a revenue of RMB 19.891 billion, a year-on-year decrease of 12.3%. The net profit was RMB 3.511 billion, a year-on-year decrease of 7.1%; earnings per share were 30.72 cents. R&D expenses increased by 7.9% to RMB 4.185 billion, accounting for 27.1% of the revenue from prescription drugs. The group has nearly 90 products in the clinical trial stage, 14 of which have submitted applications for listing, and over 30 key products are in the registration clinical stage

    AASTOCKS·
    HK
    01093
    +0.78%
    AASTOCKS·
    HK
    01093
    +0.78%
    Posts
    View More
    © 2025 Longbridge｜Disclaimer